GelStat Corp. (GSAC) Stock Price & Analysis
GelStat Corp. (GSAC) — price $0.0003 (0.00%), as of the Nov 20, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
GelStat Corp. · GSAC
GelStat Corporation researches, develops, and markets a portfolio of over-the-counter consumer healthcare products, including solutions for migraine relief, weight management, energy, and sleep disorders. The company distributes its non-prescription offerings to retailers, wholesalers, and specialty distributors.
Price as of Nov 20, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $0.0003 |
| Change on the day | 0.00% |
| Shares traded on the day | 10.0K |
Price & events
Other perspectives
Council score for GelStat (GSAC): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is GelStat (GSAC), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. GelStat Corp. (GSAC) is the company analyzed here. It employs 2 people. In Q2 FY2025 it reported revenue of $80,081 and net income of -$99,982.
What do the latest results show for GelStat (GSAC)?
Short answer · as of
The most recent reported quarter, Q2 FY2025, carried revenue of $80,081.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2025 | $80,081 | -$99,982 | $0.00 (diluted) |
| Q1 FY2025 | $64,519 | -$105,322 | $0.00 (diluted) |
| Q4 FY2024 | $117,247 | -$36,378 | $0.00 (diluted) |
| Q3 FY2024 | $117,247 | -$36,378 | $0.00 (diluted) |
What are the financial strengths and risks for GelStat (GSAC)?
Short answer
The distress and quality screens read Piotroski F 4. Trailing ratios: ROA -50.5% · current ratio 0.30.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held GSAC in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported GSAC in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: GSAC Stock
These answers are editorial: 1 of these 1 answer is drawn from the GSAC research dossier (written Jun 14, 2026 by gemini-2.5-flash). Figures in this section are not part of the source register.
How does GelStat Corporation navigate regulatory approval processes for its products?
GelStat Corporation operates within the over-the-counter (OTC) consumer healthcare product market, which is subject to specific regulatory frameworks, primarily from the U.S. Food and Drug Administration (FDA).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 10 figures on this page — 8 from Financial Modeling Prep (FMP) and 2 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com